Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Phase 2 Completed 75 enrolled Gynecologic Oncology Group National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.

Timeline

Start: 2004-04
Primary completion: 2010-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	medroxyprogesterone acetate	Other / unclassified	—	Intramuscular

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Summary

Timeline

Drugs

Indications